Business
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights into the mechanism of action of felzartamab and advancing the understanding of its disease modifying potentialExhibitor Spotlight to discuss role of CD38 cells across a range of immune-mediated kidney diseasesFelzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of immune-mediated
About this update from Biogen Inc.
[{"type":"image","alt":"Biogen Inc.","displaySize":"","headline":null,"caption":"Biogen Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/d780d0e9a7ba00777730acf271f9e937"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wH5zYbm3mC0cXQRHhCXgVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d780d0e9a7ba00777730acf271f9e937","width":300,"height":101}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights into the mechanism of action of felzartamab and advancing the understanding of its disease modifying potential","length":234,"tagName":"p"}]},{"val":[{"type":"text","content":"Exhibitor Spotlight to discuss role of CD38 cells across a range of immune-mediated kidney diseases","length":99,"tagName":"p"}]},{"val":[{"type":"text","content":"Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of immune-mediated diseases","length":175,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":508,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – will present new data from its felzartamab clinical development programs at Kidney Week 2025, the American Society of Nephrology’s (ASN) annual meeting, taking place November 5-9 in Houston, Texas. Felzartamab, an investigational anti-CD38 monoclonal antibody, is currently being evaluated in three pivotal Phase 3 studies across multiple kidney indications. The first data readout is anticipated in 2027 from TRANSCEND, a study evaluating felzartamab in adult kidney recipients diagnosed with late antibody-mediated rejection (AMR).","length":614,"tagName":"p"},{"type":"text","content":"“Following the initiation of three pivotal Phase 3 studies in 2025, Kidney Week is a pivotal moment to showcase the potential promise of our anti-CD38 platform to address a range of rare kidney diseases,” said Uptal Patel, Head of Biogen West Coast Hub. “We’re presenting first-of-its kind gene expression data and evidence of preserved humoral immunity in patients with IgA nephropathy recei...